CAMBRIDGE, Mass.† June 23, 2022 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of: Habib Dable to its board of directors. Mr. Dable, who served as Chief Executive Officer of Acceleron Pharma from 2016 to 2021, has nearly 30 years of experience in strategic leadership, commercial growth and organizational scale at global pharmaceutical and emerging biotechnology companies.
“Habib’s experience leading global, complex organizations will be incredibly valuable as Blueprint Medicines drives our next phase of transformational growth,” said Kate Haviland, Director. “We are delighted to welcome his significant expertise and perspective to our board of directors.”
“Blueprint Medicines has an impressive track record for a company of its size and age; even more impressive are the potential opportunities ahead in terms of development and commercialization,” said Mr. Dable. “I look forward to working with Blueprint’s high-profile team to capitalize on these opportunities and continue to bring the promise of precision medicine to a broad patient population.”
Mr. Dable joins Blueprint Medicines with significant leadership, growth and commercial experience gained over nearly 30 years in the biopharmaceutical industry. Most recently, as CEO at Acceleron, Mr. Dable generated more than: $10 billion in shareholder value during his 5-year tenure as CEO before successfully transitioning to Merck after the acquisition. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility and geographic footprint, including President of US Pharmaceuticals; Executive Vice President, Global Head of Specialty Medicine; Vice President, Ophthalmology; Head of the Global Launch Team, EYLEA®; Global Head, Neurology and Ophthalmology; and vice president, regional chief, hematology and cardiology. Most recently, Mr. Dable was a member of the Board of Directors of the Biotechnology Innovation Organization (BIO). Mr. Dable holds a BBA in Marketing and Finance and his MBA from the University of New Brunswick†
About blueprint medicines
Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. By adopting an approach that is both precise and agile, we create drugs that selectively target genetic factors, aiming to stay one step ahead at all stages of the disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to quickly and reproducibly translate science into a broad pipeline of precision therapies. Today we supply approved medicines directly to patients the United States and Europeand we are promoting multiple programs worldwide for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
Warning Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the strategy, goals and anticipated milestones, business plans and focus of Blueprint Medicines. The words “striving”, “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, “estimate”, “forecast”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements in this report are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that could cause actual events or results to differ materially from those expressed or implied by forward-looking statements in this report, including, but not limited to, risks and uncertainties related to the impact of the COVID-19 pandemic on Blueprint Medicines’ operations, operations, strategy, goals, and anticipated milestones, including its ongoing and planned research and discovery activities Blueprint Medicines, the ability to conduct ongoing and planned clinical trials, clinical delivery of current or future drug candidates, commercial delivery of current or future approved products, and launch, marketing and sale of current or future approved products; Blueprint Medicines’ ability and plans to continue to establish and expand commercial infrastructure and successfully launch, market and sell current or future approved products; Blueprint Medicines’ ability to successfully expand its approved indications for AYVAKIT/AYVAKYT and GAVRETO or have future approval for marketing AYVAKIT/AYVAKYT in other regions; the delay of current or planned clinical trials or the development of Blueprint Medicines’ current or future drug candidates; Blueprint Medicines’ Advancement of Multiple Efforts at an Early Stage; Blueprint Medicines’ ability to successfully demonstrate the safety and efficacy of its drug candidates and obtain timely or no approval of its drug candidates at all; the preclinical and clinical results for Blueprint Medicines drug candidates, which may not support the further development of such drug candidates, either as monotherapy or in combination with other agents, or which could influence the expected timing of data or regulatory submissions; the timing of initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; regulatory actions, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to obtain, maintain and enforce patents and other intellectual property protections for AYVAKIT/AYVAKYT, GAVRETO or other drug candidates it develops; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; Blueprint Medicines’ ability to successfully expand its business, research platform and portfolio of therapeutic candidates, and the timing and cost thereof; Blueprint Medicines’ ability to realize the expected benefits of the executive leadership transition plan; and the success of Blueprint Medicines’ current and future collaborations, acquisitions, partnerships or licensing agreements. These and other risks and uncertainties are described in more detail in the section entitled “Risk Factors” in Blueprint Medicines’ filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines’ most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings Blueprint Medicines has made or may make with the SEC. Any forward-looking statements in this report represent the views of Blueprint Medicines only as of the date of this document and should not be relied upon as a representation of Blueprint Medicines’ views as of any subsequent date. Except as required by law, Blueprint Medicines expressly disclaims any obligation to update any forward-looking statements.
Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.
View original content to download multimedia: https://www.prnewswire.com/news-releases/blueprint-medicines-appoints-habib-dable-to-its-board-of-directors-301574460.html
SOURCE Blueprint Medicines Corporation